Literature DB >> 8137265

Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.

D L Evans1, M Tilby, C Dive.   

Abstract

Immature rat thymocytes readily undergo apoptosis following exposure to many different stimuli, including agents which cause DNA damage, such as the topoisomerase II inhibitor etoposide and irradiation. We have shown previously that cells isolated from the immature rat thymus are resistant to the induction of apoptosis by the DNA-damaging agent cis-diamminedichloroplatinum(II) (cisplatin) (D. L. Evans and C. Dive, Cancer Res., 53:2133-2139, 1993). More than 85% of these thymocytes are quiescent. Here, we demonstrate that following purification of the minority subpopulation of thymocytes that are proliferating, a 2-h exposure to 50 microM cisplatin resulted in rapid apoptosis with 66% apoptotic cells by 12 h. In contrast, purified, nonproliferating thymocytes treated with cisplatin exhibited control levels of apoptosis at 12 h. Both proliferating and nonproliferating thymocytes rapidly underwent apoptosis following continuous exposure to methylprednisolone (10 microM) and etoposide (10 microM). The discrepancy in the levels of apoptosis seen in proliferating and quiescent thymocytes in response to cisplatin could not be attributed to changes in total cellular levels of cisplatin or to the number of DNA-platinum adducts which were determined, respectively, by atomic absorption spectrometry and competitive enzyme-linked immunoadsorbent assay. These results imply that in contrast to engagement of thymocyte apoptosis by methylprednisolone and etoposide, where apoptosis was proliferation independent, cisplatin-induced apoptosis depends on the presence of cells in S and G2-M phases of the cell cycle. Moreover, comparison of etoposide and cisplatin responses in thymocytes suggests that DNA damage per se may not be sufficient to induce apoptosis and that the type of DNA damage is important in this regard.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137265

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

2.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.

Authors:  D B Zamble; T Jacks; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  More pronounced salt dependence and higher reactivity for platination of the hairpin r(CGCGUUGUUCGCG) compared with d(CGCGTTGTTCGCG).

Authors:  Margareta Hägerlöf; Pal Papsai; Christine S Chow; Sofi K C Elmroth
Journal:  J Biol Inorg Chem       Date:  2006-09-05       Impact factor: 3.358

5.  Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.

Authors:  Dan-Dan Yu; Chun-Ting Wang; Hua-Shan Shi; Zhi-Yong Li; Li Pan; Qing-Zhong Yuan; Fei Leng; Yuan Wen; Xiang Chen; Yu-Quan Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-05-12

6.  Regulation of cell growth through cell cycle arrest and apoptosis in HPV 16 positive human cervical cancer cells by tea polyphenols.

Authors:  Madhulika Singh; Shilpa Tyagi; Kulpreet Bhui; Sahdeo Prasad; Yogeshwer Shukla
Journal:  Invest New Drugs       Date:  2009-03-07       Impact factor: 3.850

7.  Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway.

Authors:  Man Jiang; Cong-Yi Wang; Shuang Huang; Tianxin Yang; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11

Review 8.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

9.  cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.

Authors:  M G Ormerod; C O'Neill; D Robertson; L R Kelland; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  New insights into the kinetic resistance to anticancer agents.

Authors:  B Chauffert; M T Dimanche-Boitrel; C Garrido; M Ivarsson; M Martin; F Martin; E Solary
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.